What question did this study set out to answer?

This research aims to evaluate the efficacy of anti-EGFR antibody combination therapy versus bevacizumab in RAS wild-type metastatic colorectal cancer based on tumor location.

January 14, 2026Journal of Clinical Oncology

Efficacy of combination therapy with anti-EGFR antibody as first-line treatment for RAS wild-type metastatic colorectal cancer according to anatomical tumor location from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.

View Full Paper

Ask AI

Bookmark

This research aims to evaluate the efficacy of anti-EGFR antibody combination therapy versus bevacizumab in RAS wild-type metastatic colorectal cancer based on tumor location.
Analyzed individual patient data from the ARCAD database including 2,867 patients with RAS wild-type mCRC.
Compared outcomes of patients receiving doublet chemotherapy plus either anti-EGFR antibody or bevacizumab as first-line treatment.
Measured overall survival, progression-free survival, and overall response rate, adjusted for ECOG-PS, age, and gender.
Adding anti-EGFR antibody significantly improved overall survival and overall response rate in left-sided tumors.
No improvement in efficacy for right-sided tumors with anti-EGFR antibody compared to bevacizumab.
Efficacy trends indicated improved outcomes with anti-EGFR therapy on the distal side, but unclear results for other locations.

Authors

KYKentaro YamazakiShizuoka Cancer Center KIKenta Iguchi TMToshihiro MisumiNational Cancer Center Hospital East

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Combination therapy improves survival in left-sided metastatic colorectal cancer, indicating anatomical location impacts efficacy.

Cite This Study

Yamazaki et al. (2026) studied this question.

synapsesocial.com/papers/6966f2e313bf7a6f02c00338 https://doi.org/10.1200/jco.2026.44.2_suppl.146

View Full Paper

Ask AI

Bookmark

Efficacy of combination therapy with anti-EGFR antibody as first-line treatment for RAS wild-type metastatic colorectal cancer according to anatomical tumor location from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.

Key Points

Discussion

Implication

Cite This Study

Efficacy of combination therapy with anti-EGFR antibody as first-line treatment for RAS wild-type metastatic colorectal cancer according to anatomical tumor location from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider